<DOC>
	<DOCNO>NCT00568022</DOCNO>
	<brief_summary>The purpose study determine dose-limiting toxicity ( DLT ) , maximum tolerate dose ( MTD ) recommend Phase II dose ixabepilone combination capecitabine Japanese participant metastatic breast cancer .</brief_summary>
	<brief_title>A Phase I Study Ixabepilone Combination With Capecitabine Japanese Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Women ≥ 20 year Histologically cytologically confirm diagnosis adenocarcinoma originate breast Number prior chemotherapy line treatment metastatic setting ≥3</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>